ASCO 2019: New promising drug for second-line SCLC patients

Bjørn Henning Grønberg | ASCO 2019 | Juni 5, 2019

Speaker: Bjørn Henning Grønberg

Lurbinectedin is a novel anticancer drug that inhibits activated transcription and induces DNA double-strand breaks, leading to apoptosis. In this MEDtalk Bjørn Henning Grønberg explain, why he think, that Lurbinectedin is a new promising drug for second-line SCLC patients.